Comparison of predicted and observed mortality in patients with heart failure treated at a specialized unit

Rev Esp Cardiol (Engl Ed). 2020 Aug;73(8):652-659. doi: 10.1016/j.rec.2019.09.027. Epub 2020 Jan 21.
[Article in English, Spanish]

Abstract

Introduction and objectives: To analyze survival in heart failure (HF) patients treated at a specialized unit.

Methods: Prospective cohort-based study of HF patients treated at a specialized unit from 2011 to 2017. Observed 1- and 3-year mortality rates were compared with those predicted by the Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC) risk score.

Results: We studied 1280 patients, whose median MAGGIC risk score was 19 [interquartile range, 13-24]. Prescription rates of beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, mineralocorticoid receptor antagonists, and sacubitril-valsartan were 93%, 67%, 22%, 73%, and 16%, respectively. The MAGGIC risk score showed good discrimination for mortality at 1 year (c-statistic=0.71) and 3 years (c-statistic=0.76). Observed mortality was significantly lower than predicted mortality, both at 1 year (6.2% vs 10.9%; observed/predicted ratio=0.57; P<.001) and at 3 years (16.7% vs 27.7%; observed/predicted ratio=0.60; P<.001). This discrepancy was found in several subgroups, except in patients aged> 70 years (29.9% vs 34.7%; observed/predicted ratio=0.86; P=.126) and in patients with ejection fraction> 40% (19.6% vs 20.7%; observed/predicted ratio=0.95; P=.640).

Conclusions: Mortality in HF patients treated at a specialized clinic was significantly lower than that predicted by the MAGGIC risk score.

Keywords: Heart failure; Insuficiencia cardiaca; MAGGIC; Mortalidad; Mortality; Prognosis; Pronóstico.

Publication types

  • Meta-Analysis

MeSH terms

  • Aged
  • Aminobutyrates*
  • Angiotensin Receptor Antagonists / therapeutic use
  • Angiotensin-Converting Enzyme Inhibitors
  • Drug Combinations
  • Heart Failure*
  • Humans
  • Mineralocorticoid Receptor Antagonists
  • Prospective Studies
  • Stroke Volume
  • Tetrazoles

Substances

  • Aminobutyrates
  • Angiotensin Receptor Antagonists
  • Angiotensin-Converting Enzyme Inhibitors
  • Drug Combinations
  • Mineralocorticoid Receptor Antagonists
  • Tetrazoles